Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Arnulf

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
Frontiers in Cardiovascular Medicine|August 21, 2023
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter studyMartin Nicol, Giuseppe Vergaro, Thibaud Damy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 20, 2015
Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patientsSophie Chauvet, Frank Bridoux, Laure Ecotière, et al.
European Heart Journal. Cardiovascular Imaging|July 12, 2019
Diagnostic score of cardiac involvement in AL amyloidosisMartin Nicol, Mathilde Baudet, Stephanie Brun, et al.
Hemasphere|June 19, 2026
CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myelomaBenoît Ferment, Amani Ouedrani, Alexis Talbot, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphomaOlivier Hermine, Hervé Dombret, Joel Poupon, et al.
Ejhaem|September 2, 2022
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatmentAudrey Abecassis, Nathalie Roders, Maxime Fayon, et al.
Frontiers in Immunology|December 26, 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life studyPierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-AutogreffeJean-Paul Fermand, Sandrine Katsahian, Marine Divine, et al.
European Journal of Heart Failure|October 2, 2020
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosisMartin Nicol, Antoine Deney, Olivier Lairez, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 25, 2024
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter studyMartin Nicol, Cassiel Kitzinger, Mathilde Baudet, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Frontiers in Cardiovascular Medicine|August 21, 2023
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter studyMartin Nicol, Giuseppe Vergaro, Thibaud Damy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 20, 2015
Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patientsSophie Chauvet, Frank Bridoux, Laure Ecotière, et al.
European Heart Journal. Cardiovascular Imaging|July 12, 2019
Diagnostic score of cardiac involvement in AL amyloidosisMartin Nicol, Mathilde Baudet, Stephanie Brun, et al.
Hemasphere|June 19, 2026
CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myelomaBenoît Ferment, Amani Ouedrani, Alexis Talbot, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphomaOlivier Hermine, Hervé Dombret, Joel Poupon, et al.
Ejhaem|September 2, 2022
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatmentAudrey Abecassis, Nathalie Roders, Maxime Fayon, et al.
Frontiers in Immunology|December 26, 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life studyPierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-AutogreffeJean-Paul Fermand, Sandrine Katsahian, Marine Divine, et al.
European Journal of Heart Failure|October 2, 2020
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosisMartin Nicol, Antoine Deney, Olivier Lairez, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 25, 2024
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter studyMartin Nicol, Cassiel Kitzinger, Mathilde Baudet, et al.
Pageof 16